BDRX (Biodexa Pharmaceuticals) Notes Receivable: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDRX Biodexa Pharmaceuticals PLC BDRX
24 GF Score
Price $2.31
View Full Analysis

What is Biodexa Pharmaceuticals Notes Receivable?

Biodexa Pharmaceuticals BDRX -7.23% 24 Notes Receivable is $0.00 Mil as of Dec. 2025. GuruFocus rates BDRX with a GF Score™ of 24/100.

Biodexa Pharmaceuticals's Notes Receivable for the quarter that ended in Dec. 2025 was $0.00 Mil.

Biodexa Pharmaceuticals Notes Receivable Related Terms

Biodexa Pharmaceuticals Notes Receivable Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals Notes Receivable Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biodexa Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BDRX
24GF Score
Biodexa Pharmaceuticals PLC BDRX
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodexa Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Biodexa Pharmaceuticals (BDRX) has a Notes Receivable of $0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Biodexa Pharmaceuticals and its competitors.
Is Biodexa Pharmaceuticals' Notes Receivable too high?
Biodexa Pharmaceuticals' current Notes Receivable is $0.00 Mil. Overall, Biodexa Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Notes Receivable compare to ADTX and AAGH?
Biodexa Pharmaceuticals' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (BDRX) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Biodexa Pharmaceuticals' overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Biodexa Pharmaceuticals (BDRX), the current Notes Receivable is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biodexa Pharmaceuticals Business Description

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
24GF Score

Get the complete analysis for BDRX

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.31
Price